What Does Verona Pharma Do?

Total employees224
HeadquartersLondon
Founded2005

Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of respiratory diseases with significant unmet medical needs. Their lead product candidate, ensifentrine, is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that combines bronchodilator and anti-inflammatory activities in one compound. Verona Pharma is currently advancing ensifentrine through late-stage clinical development for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and is also exploring its potential in asthma and cystic fibrosis.

Where Is Verona Pharma's Headquarters?

Verona Pharma officeVerona Pharma officeVerona Pharma officeVerona Pharma office
*Images sourced via web search. Rights belong to original owners

HQ Function

Serves as the registered office and central hub for corporate governance, strategic decision-making, financial oversight, and global clinical development strategy.

Notable Features:

Located in the modern More London development, offering a professional environment with access to key business services and transport links. The focus is on functional, collaborative office space.

Work Culture:

A dynamic, science-driven, and patient-focused environment. Emphasis on collaboration, innovation, and achieving clinical milestones in respiratory medicine. The culture supports a lean and agile operational model.

HQ Significance:

The London headquarters is key for global strategy, investor relations (being listed on Nasdaq), and European regulatory interactions. It anchors the company's international identity.

Values Reflected in HQ: The professional and strategically located office reflects Verona Pharma's commitment to operational excellence, global outreach, and a forward-looking approach in the biopharmaceutical industry.

Location:

While Verona Pharma's main physical offices are in the UK and USA, its operational reach is global. The company conducts multinational clinical trials for its drug candidates, involving research sites and patients across North America and Europe. This global approach is essential for developing therapies for widespread conditions like COPD and for seeking regulatory approvals in multiple major markets.

Street Address:

3 More London Riverside

City:

London

State/Province:

England

Country:

United Kingdom

Where Else Does Verona Pharma Operate Around the World?

Morrisville, North Carolina, USA

Address: One Copley Parkway, Suite 460, Morrisville, NC 27560, USA

To lead and support the clinical advancement and future market access of ensifentrine in the largest pharmaceutical market, the U.S., and to engage with key stakeholders in the North American respiratory disease community.

Buying Intent Signals for Verona Pharma

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Verona Pharma? Meet the Executive Team

As of April 2025, Verona Pharma' leadership includes:

David Zaccardelli, Pharm. D. - President and Chief Executive Officer
Mark W. Hahn - Chief Financial Officer
Kathleen A. Rickard, M.D. - Chief Medical Officer
Christopher Erikson - Chief Business Officer

Who's Investing in Verona Pharma?

Verona Pharma has been backed by several prominent investors over the years, including:

RA Capital Management, L.P.
New Enterprise Associates (NEA)
Perceptive Advisors LLC
OrbiMed Advisors LLC
Access Biotechnology (Access Medical Advisers LLC)
The Vanguard Group, Inc.
BlackRock, Inc.

What Leadership Changes Has Verona Pharma Seen Recently?

Hire1
Exits0

In the past year, Verona Pharma plc has strengthened its executive team with a key appointment to lead business development efforts, underscoring its focus on strategic growth and commercial preparedness. There have been no major departures announced from the core executive leadership during this period.

New Appointments:

Christopher Erikson, Christopher Erikson joined Verona Pharma as Chief Business Officer, bringing extensive experience in biopharmaceutical corporate strategy and business development.

What Technology (Tech Stack) Is Used byVerona Pharma?

Discover the tools Verona Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Verona Pharma Email Formats and Examples

Verona Pharma plc likely utilizes common corporate email formats. While the exact primary format isn't publicly disclosed, typical structures for companies of its size and nature include first initial followed by last name, or first name dot last name, using the @veronapharma.com domain.

[firstinitial][lastname]@veronapharma.com or [first].[lastname]@veronapharma.com

Format

dzaccardelli@veronapharma.com

Example

85%

Success rate

What's the Latest News About Verona Pharma?

GlobeNewswire (Verona Pharma plc Press Release) • May 9, 2024

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma reported its financial results for the first quarter of 2024, highlighted progress with its New Drug Application (NDA) submission for ensifentrine for COPD, and outlined upcoming milestones, including the PDUFA target action date of June 26, 2024....more

GlobeNewswire (Verona Pharma plc Press Release) • March 5, 2024

Verona Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

The company announced its full-year 2023 financial results, detailed the successful NDA submission to the FDA for ensifentrine, and discussed ongoing preparations for a potential U.S. launch for the maintenance treatment of COPD....more

Fierce Biotech • January 2, 2024

Verona Pharma sees finish line for COPD drug as FDA accepts ensifentrine for review

The U.S. Food and Drug Administration (FDA) accepted Verona Pharma's New Drug Application (NDA) for ensifentrine for the maintenance treatment of patients with COPD. The FDA granted Priority Review for the application and assigned a PDUFA target action date of June 26, 2024....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Verona Pharma, are just a search away.